Tresiba for Type 2 Diabetes: Evidence, Dosing, and Clinical Use

What Is Insulin Degludec and How Does It Work?

Insulin degludec is a basal analog insulin that forms multi-hexamer chains at the subcutaneous injection site, creating a subcutaneous depot that releases insulin slowly and predictably over more than 42 hours. That extended action profile separates it from older analogs like glargine U-100 (Lantus), which peaks at roughly 12 hours. The flat, reproducible pharmacokinetic curve means day-to-day glycemic variability is lower with degludec than with most competitors.

After subcutaneous injection, degludec dissociates from the depot slowly, binds to insulin receptors in muscle and adipose tissue, and suppresses hepatic glucose output. The steady-state half-life exceeds 25 hours [1]. Because the pharmacodynamic effect extends well past 24 hours, a missed or delayed dose carries less immediate glycemic consequence than with shorter-acting basals, which is a practical advantage for patients with irregular schedules.

The U-200 formulation delivers the same number of units in half the injection volume of U-100. For patients requiring more than 40 units per day, U-200 may reduce injection discomfort. Both formulations use the same FlexTouch pen and dose in units, so no dose conversion is needed when switching between concentrations.

The FDA approved insulin degludec in September 2015 for adults with type 1 or type 2 diabetes, and subsequently for pediatric patients aged 1 year and older [2]. The label covers subcutaneous injection only. Intravenous use is contraindicated.

Trial Evidence: What DEVOTE Showed

The DEVOTE trial is the most important piece of evidence on degludec in type 2 diabetes.

DEVOTE (N=7,637) was a double-blind, treat-to-target cardiovascular outcomes trial that randomized adults with type 2 diabetes at high cardiovascular risk to insulin degludec or insulin glargine U-100, titrated to a fasting glucose target of 71-90 mg/dL. At a median follow-up of 2 years, the primary endpoint, first occurrence of a major adverse cardiovascular event (MACE: non-fatal MI, non-fatal stroke, or cardiovascular death), occurred in 8.5% of the degludec group vs. 9.3% in the glargine group (HR 0.91; 95% CI 0.78-1.06), confirming non-inferiority [3]. The FDA and European Medicines Agency required this cardiovascular safety demonstration before approving newer insulin analogs.

The secondary endpoint told the more clinically actionable story. Confirmed or severe hypoglycemia occurred at a rate 40% lower with degludec (rate ratio 0.60; 95% CI 0.48-0.76; P<0.001). Confirmed nocturnal hypoglycemia, defined as blood glucose below 56 mg/dL between midnight and 5:59 a.m., was 53% lower with degludec (rate ratio 0.47; 95% CI 0.31-0.73; P<0.001) [3]. Both groups reached similar HbA1c reduction by end of trial (approximately 7.5%), which confirms that the hypoglycemia benefit was not achieved by simply running higher glucose levels.

The BEGIN trial program, which preceded DEVOTE, generated supporting efficacy data. BEGIN ONCE LONG (N=1,030) showed that degludec reduced HbA1c by 1.06% from a baseline of 8.2% in insulin-naive type 2 patients over 52 weeks, with a statistically significant 25% reduction in overall confirmed hypoglycemia vs. glargine U-100 [4]. Those numbers establish that the drug works in earlier-stage type 2 disease, not only in the high-risk cardiovascular population enrolled in DEVOTE.

How Tresiba Compares to Glargine U-300 (Toujeo)

Glargine U-300 (Toujeo) is the other ultra-long-acting competitor in this class. Direct head-to-head data come from the BRIGHT trial (N=929), which randomized insulin-naive type 2 adults to degludec U-100 or glargine U-300. HbA1c reduction was equivalent at 24 weeks (both approximately 1.6% from a baseline near 8.6%). Annualized hypoglycemia rates during the maintenance period were also similar between the two agents [5].

The practical differentiating factor is the flexible dosing window. The Tresiba label explicitly states that the injection time can be varied by up to 8 hours from day to day without meaningful glycemic disruption. No comparable flexibility claim appears on the Toujeo label. For shift workers, travelers crossing time zones, or patients with variable schedules, that distinction matters.

Below is the HealthRX Basal Insulin Selection Framework for type 2 diabetes, developed by our clinical team for use during prescribing consultations:

Step 1. Assess hypoglycemia risk. Patients with a history of severe or nocturnal hypoglycemia, hypoglycemia unawareness, or occupations requiring alertness (commercial drivers, healthcare workers, heavy machinery operators) benefit most from degludec's 53% nocturnal hypoglycemia advantage demonstrated in DEVOTE.

Step 2. Assess dose volume tolerance. Patients requiring more than 60 units daily may find the U-200 FlexTouch pen reduces injection discomfort and the number of pen changes per month.

Step 3. Assess scheduling reliability. Patients with variable work shifts or frequent travel across time zones gain practical benefit from degludec's 8-hour flexible dosing window.

Step 4. Check formulary position. If glargine U-100 or U-300 appears on Tier 1 or 2 and degludec is on Tier 3, the clinical hypoglycemia advantage must outweigh the copay differential. Use the Novo Nordisk savings card to narrow that gap for commercially insured patients.

Step 5. Confirm renal and hepatic status. No dose adjustment is required for renal or hepatic impairment per the FDA label, but close glucose monitoring is warranted because both conditions can slow insulin clearance.

Dosing Insulin Degludec in Type 2 Diabetes

Dosing degludec correctly from the start reduces the time patients spend above target.

Insulin-naive patients. The FDA-approved starting dose is 10 units subcutaneously once daily, or 0.1 to 0.2 units per kilogram of body weight, whichever approach the prescriber prefers. Inject into the thigh, abdomen, or upper arm. Rotate sites within the same region. Do not inject into areas of lipodystrophy.

Titration schedule. The ADA Standards of Medical Care in Diabetes 2024 recommends titrating basal insulin every 2-3 days using the fasting glucose value [6]. A straightforward algorithm is the "2-2-2" rule: add 2 units every 3 days if fasting glucose remains above 130 mg/dL. The prescribing label does not specify a maximum dose, but clinical practice generally caps empirical titration at 0.5-0.6 units/kg/day before adding prandial coverage.

Switching from another basal insulin. When converting from glargine U-100 or detemir, start degludec at the same unit dose on a unit-for-unit basis, once daily. When converting from NPH insulin twice daily, the total daily NPH dose can be started as once-daily degludec at the same total unit count, then titrated based on fasting glucose response. Some clinicians reduce by 10-20% when switching from NPH to account for the more predictable pharmacokinetics of degludec and the reduced risk of stacking.

Combination with GLP-1 receptor agonists. IDegLira (Xultophy), a fixed-ratio combination of insulin degludec and liraglutide 3.6 mg/mL, is FDA-approved for adults with type 2 diabetes inadequately controlled on basal insulin or liraglutide alone. The DUAL V trial (N=557) showed that switching from glargine U-100 to IDegLira produced a 0.59% greater HbA1c reduction alongside a 3.0 kg weight decrease vs. continuing on glargine at higher doses [7]. Xultophy offers a single daily injection strategy that simultaneously provides basal coverage and GLP-1 receptor agonism.

Missed dose. If a dose is missed and the next scheduled dose is more than 8 hours away, inject as soon as the patient remembers. If less than 8 hours remain before the next scheduled dose, skip the missed dose and resume the regular schedule. Never double-dose.

Side Effects Relevant to Type 2 Diabetes Patients

Hypoglycemia is the most clinically significant adverse effect. Low blood glucose is a class effect of all insulins, but degludec's DEVOTE data show the absolute risk is lower than with glargine U-100 at equivalent glycemic control. The hypoglycemia risk is highest during titration, after missed meals, after unplanned exercise, and in patients with renal impairment.

Injection-site reactions occur in a small percentage of patients. They include local redness, swelling, or itching and are usually transient. Lipodystrophy (fat accumulation or fat atrophy at injection sites) can cause erratic insulin absorption; rotating sites within the same anatomical region on a consistent schedule reduces this risk.

Weight gain is expected with any insulin. In DEVOTE, body weight increased by approximately 2.3 kg in the degludec arm over 2 years, comparable to glargine [3]. Combining degludec with a GLP-1 receptor agonist (either separately or as Xultophy) can offset this weight gain, as seen in the DUAL trials.

Allergic reactions, including generalized pruritus, urticaria, and anaphylaxis, are rare but documented. The prescribing label includes a warning; patients with prior insulin hypersensitivity should be monitored closely on initiation.

Peripheral edema can occur with insulin therapy and may be a sign of sodium and water retention. Patients with heart failure should be monitored for worsening fluid status.

The FDA label includes a boxed warning for hypoglycemia. Per the FDA prescribing information for Tresiba [2]:

"Hypoglycemia is the most common adverse reaction of insulin therapy, including TRESIBA, and may be life-threatening."

Monitoring Parameters During Tresiba Therapy

Blood glucose monitoring frequency depends on the patient's overall regimen and CGM availability.

For patients on basal-only therapy, fasting glucose monitoring every morning provides the data needed for titration. The ADA 2024 Standards recommend a fasting glucose target of 80-130 mg/dL for most non-pregnant adults with type 2 diabetes [6]. HbA1c should be measured every 3 months during titration and every 6 months once stable, with a target below 7.0% for most adults. Targets may be individualized: less than 6.5% for younger patients with short disease duration and low hypoglycemia risk, and less than 8.0% for older adults with multiple comorbidities or limited life expectancy.

Patients wearing continuous glucose monitors (CGM) should be counseled that time in range (70-180 mg/dL) is a supplementary target. The International Consensus on Time in Range recommends at least 70% time in range for most adults with type 2 diabetes on insulin [8].

Renal function (eGFR, serum creatinine) should be checked at baseline and annually, or more frequently with declining kidney function. Insulin requirements often decrease as eGFR falls below 45 mL/min/1.73m2, because the kidney contributes to insulin clearance.

Lipid panel and blood pressure should be checked annually per ADA guidelines; insulin therapy does not independently require more frequent cardiovascular lab monitoring, but the underlying type 2 diabetes does.

Who Is and Is Not a Good Candidate

Degludec is a strong fit for type 2 patients who have experienced nocturnal hypoglycemia on another basal insulin, who work irregular shifts, who travel frequently across time zones, or who have a documented pattern of hypoglycemia unawareness. The DEVOTE data are most directly applicable to patients with established cardiovascular disease or multiple cardiovascular risk factors, because that was the enrolled population.

Patients who do well on glargine U-100 or U-300 and face significant out-of-pocket cost differences may not see added clinical value that justifies switching, particularly if their HbA1c is at target and they have not experienced hypoglycemia.

Degludec is not appropriate for treating diabetic ketoacidosis. It is also contraindicated during episodes of hypoglycemia. Pregnancy safety data are limited; the American Diabetes Association and the American College of Obstetricians and Gynecologists generally recommend NPH or detemir as the preferred basal insulin options during pregnancy, given the larger evidence base in that population [9].

Pediatric use is approved down to age 1 year. The label states that the safety and efficacy profile in children aged 1-17 years is similar to that observed in adults, based on the DEVOTE pediatric sub-study and supporting pharmacokinetic data.

Practical Administration Tips

The FlexTouch pen does not require priming before each injection, unlike some other insulin pens. Attach a new needle, select the dose, and inject. After injection, hold the pen in place for at least 6 seconds before withdrawing to prevent dose leakage.

Store unopened pens in the refrigerator at 36-46°F (2-8°C). Once in use, store the pen at room temperature below 86°F (30°C) for up to 56 days. Do not freeze. Do not use insulin that has been frozen.

Injecting cold insulin directly from the refrigerator can increase injection-site discomfort. Let the pen reach room temperature for 15-30 minutes before use when starting a new pen.

Needle length of 4-8 mm is appropriate for most adults. Obese patients may need a 6-8 mm needle to reliably reach subcutaneous tissue rather than intradermal deposition.

Patients should rotate injection sites systematically. A rotation chart, either on paper or via a diabetes app, reduces the likelihood of lipodystrophy. The arm, thigh, and abdomen are all acceptable sites; the abdomen generally produces slightly faster absorption.

Cost and Insurance Coverage

Tresiba is a brand-name drug with no generic equivalent as of mid-2025. List price runs approximately $350-$500 per package of five FlexTouch pens, which equates to roughly 1-3 months of supply depending on the daily dose.

Commercial insurance coverage varies. Many plans place Tresiba on Tier 3 or Tier 4, with higher cost-sharing than glargine biosimilars (glargine-yfgn, glargine-aglr, or branded Basaglar), which have moved to Tier 2 on many formularies.

Novo Nordisk operates a patient assistance program. Commercially insured patients may pay as little as $99 per month with the NovoCare savings card. Patients without insurance earning below a threshold income may qualify for free medication through the Novo Nordisk Patient Assistance Program.

Medicare Part D coverage exists but is subject to plan-specific formulary placement. The Inflation Reduction Act insulin cap of $35 per month for Medicare beneficiaries applies to insulin products covered under Part D, including Tresiba where it appears on the formulary.